Diamyd Replaces CEO
Diamyd Medical AB announces that Elisabeth Lindner today has left her
position as President and CEO of the Company. Excecutive Vice President
Peter Zerhouni has been appointed Acting President and CEO.
Elisabeth Lindner has left her position as President and CEO due to
disagreement with the Board concerning certain important matters.
Peter Zerhouni has been involved in all aspects of the Company since
2006, including a key role in driving the Company's business and
clinical trials forward. Zerhouni has a combined financial and
biotechnology background, and studied at Lund University in Sweden, and
University of California at Berkeley in USA. He has been working as head
of business development for the last three years and played an
instrumental part in securing the Company's agreement with
Ortho-McNeil-Janssen Pharmaceuticals, Inc. to develop and commercialize
the Diamyd® diabetes therapy.
The Board acknowledges Elisabeth Lindner's contributions to successfully
progress the Phase III program with Diamyd® in recent-onset type 1
diabetes. Top line results from a European Phase III study are expected
to be available later this spring. Work is currently ongoing to compile
and process all the study data, which remains fully blinded to
Investigators and patients as well as to Diamyd Medical AB.
For more information, please contact:
Anders Essen-Möller, Chairman, Diamyd Medical AB (publ.)
Phone: +46 8 661 0026
For pictures and press material, please contact:
Andreas Ericsson, Diamyd Medical AB (publ.)
andreas.ericsson@diamyd.com
Phone: +46 8 661 0026
